Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose Dense vs Standard Capecitabine in Metastatic Breast and GI Cancers
NCT02595320Phase 2Unknown
- Sponsor
- Qamar Khan
- Start
- Oct 2015
- Primary completion
- Dec 2022
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of capecitabine in breast cancer, gastrointestinal cancer, sponsored by Qamar Khan. Status: unknown.
02
Drugs
capecitabine
03
Conditions
breast cancergastrointestinal cancer
Beyond the preview
Go deeper on NCT02595320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02595320.